tirzepatide heart for Failure in Patients with Obesity Obesity and heart failure: what
Description
Materials and methods This randomised, doubleblind, placebocontrolled, twoperiod crossover trial investigated the effects of 12 weeks of treatment with onceweekly subcutaneous semaglutide, doseescalated to 1.0 mg, in 30 subjects with obesity
Im confident this is first of many conversations well be having about GLP-1 medications for type 1 diabetes
Similar content being viewed by others Introduction Reducing the incidence of long-term complications attributable to type 2 diabetes is vital to minimising the high and increasing expenditure associated with the disease
Clinically obvious signs of inability to protect the airway (e.g
